Hester Biosciences Peer Comparison

NSE: HESTERBIO | BSE: 524669

₹2,236.50

₹40.10 (1.83%)

As on 16-Oct-2026IST

Market cap

₹1,906 Cr

Revenue (TTM)

₹326 Cr

P/E Ratio

P/B Ratio

4.2

Div. Yield

0.5 %

Edit

	Hester Biosciences	Sequent Scientific	NGL Fine-Chem	Emcure Pharmaceuticals	Wockhardt
Market cap (₹ Cr)	1,906	9,986	1,736	34,586	31,674
Revenue (₹ Cr)	326	3,149	536	9,683	3,564
Net Profit (₹ Cr)	129.56	213.79	57.20	1,018.97	414.00
Net Margin (%)	38.70	6.70	10.35	10.47	11.23
RoE (%)	14.64	10.42	18.17	21.30	8.38
Price to Earnings	13.99	58.34	30.35	34.20	77.44
Price-To-Book	4.19	3.55	4.99	6.61	6.29

Income Statement (₹ Cr)

	Hester Biosciences	Sequent Scientific	NGL Fine-Chem	Emcure Pharmaceuticals	Wockhardt
Operating Revenue	325.74	3,148.72	536.16	9,683.45	3,564.00
Total Income	334.75	3,189.08	552.72	9,730.84	3,686.00
Total Expenditure	239.12	2,554.78	451.99	7,739.53	2,792.00
EBITDA	86.62	593.94	84.17	1,943.92	772.00
Depreciation	21.74	196.17	20.57	425.10	226.00
EBIT	64.88	397.77	63.60	1,518.82	546.00
Interest	12.20	57.29	4.23	148.45	217.00
Other Income	9.01	40.36	16.55	47.39	122.00
Exceptional Items	88.29	-42.96	0.00	-27.85	12.00
Profit before Tax	149.97	337.88	75.92	1,389.91	463.00
Provision for Tax	20.41	124.09	18.72	370.94	49.00
Profit after Tax	129.56	213.79	57.20	1,018.97	414.00

	Hester Biosciences	Sequent Scientific	NGL Fine-Chem	Emcure Pharmaceuticals	Wockhardt
Shareholder's Funds	360.24	2,911.06	329.23	4,950.03	4,940.00
Minority Interest	-0.74	-42.63	0.00	-7.58	-5.00
Non-Current Liabilities	157.67	567.76	66.25	723.57	1,712.00
Current Liabilities	152.48	945.90	150.02	3,912.24	1,622.00
Total Liabilities	677.94	4,595.61	560.46	9,514.48	8,578.00

	Hester Biosciences	Sequent Scientific	NGL Fine-Chem	Emcure Pharmaceuticals	Wockhardt
Non-Current Assets	463.36	2,182.30	259.33	3,392.16	5,343.00
Current Assets	208.56	2,254.55	276.39	5,612.10	2,606.00
Total Assets	677.94	4,595.61	560.46	9,514.48	8,578.00
Total Debt*	188.26	435.81	122.50	1,204.08	2,125.00
Net Current Assets	56.08	1,308.65	126.37	1,699.86	984.00
Contingent Liabilities	--	26.69	0.80	258.92	768.26

	Hester Biosciences	Sequent Scientific	NGL Fine-Chem	Emcure Pharmaceuticals	Wockhardt
Cash From Operating Activities	64.14	322.91	43.32	943.55	390.00
Cash Flow from Investing Activities	-2.87	-84.12	-70.59	-1,193.06	-241.00
Cash from Financing Activities	-48.79	-123.33	29.55	343.43	-54.00
Net Cash Inflow / Outflow	12.48	115.46	2.27	93.92	95.00

	Hester Biosciences	Sequent Scientific	NGL Fine-Chem	Emcure Pharmaceuticals	Wockhardt
ROCE (%)	16.21	13.10	16.88	25.25	6.79
ROE (%)	14.64	10.42	18.17	21.30	8.38
ROA (%)	19.46	6.86	11.69	11.42	4.94
EBIT Margin (%)	19.92	12.63	11.86	15.68	15.32
Net Margin (%)	38.70	6.70	10.35	10.47	11.23
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Hester Biosciences	Sequent Scientific	NGL Fine-Chem	Emcure Pharmaceuticals	Wockhardt
Revenue Growth (%)	4.09	16.33	40.45	18.36	18.37
EBIT Growth (%)	31.42	127.71	214.27	30.43	252.26
Net Profit Growth (%)	277.20	303.76	174.02	32.39	377.85
EPS Growth (%)	35.90	3.66	174.02	36.68	1,001.33
Book Value Growth (%)	14.63	20.14	16.57	11.36	13.47

	Hester Biosciences	Sequent Scientific	NGL Fine-Chem	Emcure Pharmaceuticals	Wockhardt
Price / Earnings	37.30	48.07	30.35	33.49	79.49
Price / Book Value	4.19	3.55	4.99	6.61	6.29
Dividend Yield (%)	0.49	0.00	0.06	0.20	0.00
EV/EBITDA	24.10	17.09	21.55	18.34	42.92
Market Cap (₹ Cr)	1,074.13	8,003.17	1,279.54	30,257.56	19,071.62

	Hester Biosciences	Sequent Scientific	NGL Fine-Chem	Emcure Pharmaceuticals	Wockhardt
Debt to Equity	0.25	0.10	0.17	0.05	0.31
Short term debt to equity ratio	0.07	0.04	0.16	0.16	0.09
Current Ratio	1.37	2.38	1.84	1.43	1.61
Quick Ratio	0.89	1.53	1.37	0.82	1.06
Interest Coverage	13.29	6.90	18.95	10.36	3.13

	Hester Biosciences	Sequent Scientific	NGL Fine-Chem	Emcure Pharmaceuticals	Wockhardt
Debtors to sales (%)	29.27	33.20	24.41	26.46	16.50
Asset Turnover	0.49	1.01	1.10	1.09	0.43
Receivable days	92.43	98.80	77.86	88.68	58.75
Inventory Days	78.37	79.26	44.28	84.11	75.82
Payable days	120.46	126.90	88.92	176.65	186.21
Cash Conversion Cycle	50.33	51.16	33.22	-3.86	-51.64

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.